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ABSTRACT
Background Neurofibroma consists of abundant extracellular matrix and many types of 
cells, including Schwann cells (SCs), mast cells (MCs), fibroblasts and endothelial cells. 
As SCs have been found to be the cell of origin for neurofibroma, how MCs may migrate 
into the tumor has not been fully clarified. Given that chemokine receptor CCR3 is 
found predominantly expressed by differentiated MCs, we postulated that CCR3 may 
play a role in the homing of MCs to neurofibroma. The goal of this study is to investi-
gate the possible involvement of chemokine receptor CCR3 in the migration of MCs to 
the neurofibroma.
Methods Expressional and functional assays for CCR3 and its ligands were performed 
on MCs and SCs.
Results By real-time quantitative polymerase chain reaction and enzyme-linked immu-
nosorbent assay, we found one of the CCR3 ligand, CCL7 was highly expressed by 
murine SC cell line SW10, and also moderately expressed by MCs. In serial chemotaxis 
assays, MCs were found specifically responsive to CCL7 and also condition medium 
from SW10 cells, indicating SCs may attract MCs by CCR3-mediated cell migration.
Conclusion The interaction of CCR3 and CCL7 may play important roles for MC migra-
tion toward SC in the neurofibroma.
Copyright © 2010, Taiwanese Dermatological Association. 
Published by Elsevier Taiwan LLC. All rights reserved.
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Introduction
Neurofibromatosis 1 (NF1), also known as von Recklinghausen’s 
disease, is the most common neurocutaneous disorder mainly 
featured by localized or extensive cutaneous, intraneural, 
or even visceral neurofibromas which often cause life-long 
suffering of severe disfiguring and loss of function in patients.1 
The NF1 gene, a tumor suppressor gene, has been identified 
as the main pathogenic gene for NF1 (in loss of function),2 
and its gene product, the neurofibromin protein, has been 
characterized as an antagonist of Ras protein,3,4 a well-known 
oncogene product signaling cell proliferation and apoptosis 
resistance.5
Characterized by cellular heterogeneity, neurofibroma is 
composed of many types of cells including Schwann cells 
(SCs), mast cells (MCs), fibroblasts, endothelial cells (ECs), and 
perineural cells.1 Several lines of evidences have indicated 
that SCs appear to be the major progenitor cells for neurofi-
broma formation; both NF1 gene copies have been shown 
inactivated exclusively in the SCs, whereas a wild-type gene 
is still retained in the other neurofibroma cells, including 
fibroblasts.6 Moreover, in vitro studies have revealed several 
unique tumorigenic features of the SCs in neurofibroma, 
including delayed senescence, lack of density-limited growth, 
and the tendency to form proliferative cell aggregates.7 
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Functionally, it has also been shown that the neurofibroma 
SCs promote angiogenesis and invade basement membranes, 
while normal SCs and fibroblasts from neurofibroma do not.8
On the other hand, our knowledge about how MCs 
become one of the constituent cells of the neurofibroma and 
whether they may also contribute to neurofibroma tumor 
progression remains limited. Normally, MCs are originally 
derived from bone marrow progenitors, circulate in the pe-
ripheral blood as undifferentiated but committed progenitors, 
and then migrate into peripheral tissues (e.g. lung, gastroin-
testinal tract, or skin) where they mature into either mucosal-
type MCs (MMCs) or connective tissue-type MCs (CTMCs).9 
MCs have long been considered as a key inflammatory 
effector cells in human allergic diseases like asthma; never-
theless, recent studies have also demonstrated many types 
of inflammatory cells, including MCs, play important roles in 
the initiation, progression, and angiogenesis of tumors.10−12
Chemokine receptor belongs to the family of seven-
transmembrane, G protein-coupled receptor. Long well known 
for its ability to mediate directional migration of leukocyte, 
chemokine receptor has been shown to be essential for MC 
trafficking to airways and intestine in several constitutive or 
pathological conditions.13,14 For example, several recent 
reports have demonstrated that chemokine receptor CCR3 
plays multiple essential roles in MCs, including trafficking of 
MC progenitors and selective modification of MC pheno-
type and effector function.15−20 Importantly, Romagnani et al20 
have demonstrated that CCR3 is primarily expressed by 
CTMCs distributed in skin and intestine submucosa, but 
not MMCs in intestine mucosa and lung, and CCR3 is the 
only chemokine receptor maintained in CTMCs after differ-
entiation to mature cells.20 We thus hypothesized that 
CCR3 may also play a role in the MC migration/homing to the 
neurofibroma. In present study, we have investigated the 
expressional status of CCR3 and its ligands in MCs and SCs 
respectively, followed by in vitro assays to test whether the 
migration and cell survival of MCs may be mediated in a 
CCR3-dependent fashion. Our data have provided further 
evidences that the chemokine receptor may also play a pivotal 
role in the process of MC migration to neurofibroma.
Materials and methods
Antibodies, reagents, and cell lines
Recombinant murine IL-3, recombinant murine CCL7 (also 
known as monocyte chemotactic protein-3), and recom-
binant murine stem cell factor (SCF) were purchased from 
Peprotech (Rockyhill, NJ, USA). Abs used in FACS analysis 
were anti-mouse CCR3 (R&D Systems, Minneapolis, MN, 
USA), anti-mouse FcεRIα (eBioscience, San Diego, CA, USA), 
and anti-mouse CD117 (Kit; eBioscience). The isotype control 
Abs were hamster IgG (Biolegend, San Diego, CA), rat IgG 
2A (R&D Systems), goat IgG (R&D Systems), mouse IgG1 
(Rockland, Gilbertsville, PA, USA), and rat IgG 2A (eBio-
science). Anti-mouse CCL7 polyclonal Ab was from Biovision 
(Mountain View, CA), and HRP-conjugated anti-goat IgG 
was from Rockland. Other reagents used were calcein AM 
(Molecular Probe/Invitrogen, Rockville, MD, USA), and per-
tussus toxin (Calbiochem, San Diego, CA). The murine cell 
lines, including SC line (SW10), cytotoxic T cell line (CTLL-2), 
and immature dendritic cell line (JAWSII), were originally 
from American Type Culture Collection (Manassas, VA, USA) 
and purchased from local provider National Health Research 
Institute Cell Bank (Hsin Chu, Taiwan). All cell lines were cul-
tured in growth media according to instruction of provider.
Isolation of mouse MCs
Mouse bone marrow-derived CTMCs (BM-CTMCs) were 
isolated using BALB/c mice (6–8-week-old female) as pre-
viously described with modification,21 under the approval 
of institutional animal care and use committee. Bone mar-
row cells were suspended in RPMI 1640 medium with 10% 
fetal bovine serum and cultured with SCF (40 ng/mL), and 
IL-4 (300 U/mL). Cells were incubated at 37ºC in a 5% CO2 
humidified atmosphere. Four weeks later, the cells were ana-
lyzed by flow cytometry for the expression of FcεRIα and Kit 
to characterize the differentiation phenotypes of BM-CTMCs. 
MCs in culture up to 4–8 weeks were used for experiments.
Detection of CCR3 and CCL7 expression by 
quantitative PCR (qPCR) and flow cytometry
CCR3 expression by BM-CTMCs and CC Chemokines 
(CCL3, 7, 8, 13) expression by SW10 SCs were detected by 
real-time qPCR. Total RNA was isolated from cell pellets 
using RNeasy kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. First-strand cDNA was gener-
ated from total RNA using commercial kit for reverse tran-
scription (Superscript First-Strand Synthesis System; Invitrogen, 
Frederick, MD, USA). qPCR was performed using an ABI 
PRISM 7900 DNA Sequence Detection System and SYBR 
Green (Applied Biosystems, Foster City, CA) to quantify the 
PCR product as previously described.22 Mouse glyceralde-
hyde 3-phosphate dehydrogenase (G3PDH) was used as an 
internal control. The primer pairs for CCL3 (5-GCTTCTCC
TACAGCCGGAAGA-3 and 5-GCAAAGGCTGCTGGTTTC
A-3), CCL7 (5-GGA TCTCTGCCACGCTTCTG-3 and 5-G
GCCCACACTTGGATGCT-3), CCL8 (5-AGCTACGAGAGA
ATCAACAATATCCA-3 and 5-CAGAGAGACATACCCTGCT
TGGT-3), CCL13 (5-GAGACTCCCTCTGTGAATGTAATTC
C-3 and 5-GCTGCCCGGCACATCTT-3), CCR3 (5-GGCT
CCTGCCTCCACTGTAC-3 and 5-TGAGGATCAACACAAC
CATTATGTT-3), and G3PDH (CGTGTTCCTACCCCCAATGT 
and TGTCATCATACTTGGCAGGTTTCT) were designed using 
Primer Express software (Applied Biosystems). Cycle threshold 
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numbers (Ct) were derived from the exponential phase of 
PCR amplification. Fold differences in expression of gene x in 
cell populations y and z were derived by 2k, where k = (Ctx − 
CtG3PDH) population y − (Ctx − CtG3PDH) population z. For 
detection of CCR3 expression by BM-CTMCs at protein level, 
BM-CTMCs were stained with fluorescein-conjugated anti-
mouse CCR3 antibody and were analyzed by flow cytometry.
Detection of the expression of CCR3 and CCL7 in 
neurofibroma lesions
Tissue immunostain using anti-CCR3 antibody (Abcam, 
Cambridge, MA) and anti-CCL7 antibody (GenWay, San 
Diego, CA) was performed using 4-μm or 6-μm sections from 
the frozen (for immunofluorescent studies) biopsied specimens 
from neurofibroma lesions in NF1 patients, with informed 
consent and the approval of institutional review committee. 
Immunofluoresent staining was performed with confocal 
microscopy as previously described.23 Briefly, frozen sections 
from representative neurofibroma lesions were stained with 
either anti-CCR3 or anti-CCL7 antibodies, followed by stain 
with respective FITC-conjugated secondary antibodies. Anti-
glial fibrillary acidic protein (GFAP) and anti-MC tryptase 
antibody, from Abcam and Dako (Glostrup, Denmark) re-
spectively, were used to stain and specifically label SCs and 
MCs with Rhodamine-conjugated secondary antibodies. 4’,6-
diamidino-2-phenylindole (DAPI) was used to label cell 
nuclei.
Detection of CCL7 expression by enzyme-linked 
immunosorbent assay
For CCL7 detection by ELISA, 96-well microtitre plates (Nunc-
Immuno Module F8 MaxiSorp, NalgeNunc International, 
Roskilde, Denmark) were coated with 100-μL of (per well) 
SW10 culture medium. The wells were incubated overnight at 
room temperature. After washing, the wells were incubated 
with blocking solution (1% BSA/PBS) for 1 hour. 100-μL 
anti-mouse CCL7 polyclonal antibody (2 μg/mL) was then 
added to each well. After incubation for 2 hours, 100 μL of 
HRP-conjugated anti-goat IgG (1:35 000) was added. The 
plate was developed with TMB Plus, Liquid-1 Component 
(Amresco Inc., Solon, OH, USA) for 20 minutes. The reaction 
was then blocked with Stop Solution (1N H2SO4). The ab-
sorbance was measured by microplate reader at 450 nm.
Chemotaxis assay
The chemotaxis assay was performed as previously de-
scribed.24 The migration of BM-CTMCs in response to CCL7 
was analyzed using 96-well (8-μm pore size) ChemoTx 
Disposable Chemotaxis System (Neuro Probe; Gaithersburg, 
MD). MCs (2.5 × 104) were assessed with exposure to re-
combinant mouse CCL7 at various concentrations or SW10 
conditioned medium, with or without other reagents (to test 
CCL7-dependence) including pertussis toxin (PTX) (100 ng/
mL), anti-mouse CCL7 neutralizing antibody (40 μg/mL), and 
goat IgG isotype control (40 μg/mL). BM-CTMCs were la-
beled with calcein AM, loaded atop of the filter, and the che-
motaxis well was incubated at 37ºC for 3 hours. The number 
of fluorescent MCs migrating through filter was quantified 
by direct counting in three or more randomly selected micro-
scopic fields (40 × objective).21
CCR3 signaling pathways in MCs
BM-CTMCs (1 × 106/mL) were cultured in 24-well plates for 
4 hours at 37º in serum-free medium and then treated with 
CCL7 (200 ng/mL), with or without neutralizing anti-CCL7. 
Cells were harvested at various time points (0, 1, 5, 10, 15, and 
30 min) for total protein extraction. The Coomassie Protein 
Assay Kit (PIERCE, Rockford, IL) was used to measure the 
protein. Cell lysates containing 30-μg protein were separated 
by 8% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and transferred to PVDF membranes. Membranes 
were blotted with various antibodies, including antipan-Akt, 
anti-phospho-Akt, anti-pan-ERK1/ERK2, and antiphospho-
ERK1/ERK2 (R&D systems) at 4ºC overnight. Secondary an-
tibodies were then added, and the bands were developed 
by enhanced chemiluminescence.
Statistical analysis
The data are presented as mean ± SD. Data were analyzed 
by Student’s t tests (two-sided, parametric). Statistical signifi-
cance was determined at p < 0.05. Experiments were per-
formed at least three times. Representative data are presented.
Results
CCR3 expression by BM-CTMCs
Using qPCR and flow cytometry, we have measured the ex-
pression of chemokine receptor CCR3 by mouse BM-
CTMCs. BM-CTMCs were isolated and cultured as previously 
reported,21 with about 88% of cell population showing the 
expression of phenotype markers including Kit, FcεRIa (data 
not shown) and heparin-containing granules.21,25 Relatively 
high expression of CCR3 by BM-CTMCs has been demon-
strated using qPCR (Figure 1A), in comparison with other 
type of murine inflammatory cells including CTLL-2 (cyto-
toxic T cell line) and JAWSII (immature dendritic cell line), 
as these two cell types have also been reported to express 
CCR3.26,27 CCR3 expression was also detected by flow cy-
tometry (Figure 1B) and by immunostain (Figures 1C and D) 
using samples of neurofibroma lesions. Representative lesions 
were studied with both immunohistochemical (not shown) 
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and immunofluorescent (Figures 1C and D) methods, using 
isotype control (for anti-CCR3) and double staining (to label 
MCs), and the expression of CCR3 by MCs was thus confirmed.
CCL7 expression by SCs and MCs
In order to determine whether SCs, the progenitor cells for 
neurofibroma, may attract MCs through the interaction of 
CCR3 and its ligand (s), the expressional status of all the four 
ligands for CCR3 (CCL3, CCL7, CCL8, and CCL13) in SW10 
SC cells was examined by qPCR. As shown in Figure 2A, 
CCL7, but not other ligands for CCR3, was found predomi-
nantly expressed by SW10. CCL7 expression by SCs was 
further confirmed by ELISA, showing CCL7 secretion in con-
ditioned medium derived from SW10 culture (Figure 2B).
To further determined the CCL7 expression in the neurofi-
broma lesions, representative lesions were studied with both 
immunohistochemical (not shown) and immunofluorescent 
(Figure 2C) methods as aforementioned, using isotype control 
(for anti-CCL7) and double staining (to label SCs and MCs) to 
confirm the expression of CCL7 by SCs. As shown in Figure 2C, 
immunofluorescent study by confocal microscopy demon-
strated CCL7 expression around SCs and MCs (not shown).
MCs are specifically responsive to CCL7 and 
conditioned medium from SCs
We next determined whether CCR3 may be functionally ac-
tive in BM-CTMCs. By standard chemotaxis assay, BM-CTMCs 
demonstrated typical chemotaxis responses to CCL7 at var-
ious concentrations (Figure 3A). The chemotaxis response 
was specific to CCL7, as it could be blocked by neutralizing 
anti-CCL7 Antibody and PTX (a nonspecific blocking agent 
for chemokine receptors), but not by isotype control IgG 
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Figure 1 Expression of CCR3 by mast cells (MC). (A) CCR3 expression by bone marrow–derived connective tissue–type MCs (BM-CTMC) was 
detected by real-time quantitative polymerase chain reaction, in comparison with other murine immunological/inflammatory types of cells (CTLL-
2, cytotoxic T cell line; JAWSII, immature dendritic cell line). Relative expression level for each cell type is shown atop the black bars. CCR3 ex-
pression by MCs was also detected by flow cytometry (B) Dotted line indicates isotype IgG for anti-CCR3; solid area indicates anti-CCR3 antibody 
and immunostain. (C) CCR3 expression by MCs detected by immunofluoresent staining. Representative frozen sections from neurofibroma lesions 
were stained with FITC-conjugated anti-CCR3 antibodies (left upper panel, green). Rhodamine-conjugated anti-MC tryptase antibodies were used 
to stain and specifically label MCs (right upper panel, red). Colocalization (merged color) of CCR3, MCs, and cell nuclei (DAPI stain, blue; left 
lower panel) was shown in right lower panel. White arrow indicates a representative MC showing colocalization of CCR3 and MC tryptase. (D) 
Isotype control study for anti-CCR3 staining with similar setting as in (C), demonstrating insignificant baseline stain (left upper panel). White arrow 
indicates a representative MC. Immunofluorescent staining was detected by confocal microscopy.
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(Figure 3B). Moreover, BM-CTMCs also showed specific re-
sponses to the SW10-derived conditioned medium by 
chemotaxis assay (Figure 3C), as the chemotaxis migration 
could also be blocked by anti-CCL7 and PTX, but not by 
isotype control. These results indicate SW10 may attract 
BM-CTMCs through chemotaxis mediated by CCR3-CCL7 
interaction, thus supporting that CCR3 may play an impor-
tant role in MC migration and homing to neurofibroma.
Immunoblotting for tracing CCR3 signaling 
pathway in response to CCL7
To further explore the involvement of CCR3/CCL7 in the 
migration/homing and the survival of MCs, we next investi-
gated the possible signaling events of BM-CTMCs in re-
sponse to CCL7 by immunoblotting. In response to CCL7 
treatment, the time-dependent accumulation of phosphor-
ylated Erk1/2 was found in BM-CTMCs (Figure 4, upper 
panel). Moreover, the phosphorylation of another important 
signaling effector molecule, Akt was also found increased 
above basal level with the presence of CCL7 (Figure 4, 
lower panel). These reactions were CCL7-specific, as they 
could be blocked by neutralizing anti-CCL7 (not shown).
Discussion
Long well-known as a key player for allergic disease like 
asthma, MC has been found to be involved in the induction 
of both innate and adaptive immune response and actively 
mediating an expanding list of diverse diseases with au-
toimmune, inflammatory, or even neoplastic natures.9−11 
Although the increased number of MCs in neurofibroma is a 
long well-known phenomenon,28 the mechanism to mediate 
the migration and homing of MC to neurofibroma has not 
been elucidated until recent years. In a recent study, by using 
nullizygous (NF1−/−) SCs and heterozygous (NF1+/−) MCs 
from transgene mice, Yang et al29 have shown that neurofi-
bromin-deficient SCs secret more Kit ligand (namely SCF), 
which may serve as a chemoattractant for MCs expressing 
Kit receptor and stimulate MC migration in vitro. This study 
has provided a theoretical base which not only provides an 
explanation, at least in part, to the phenomenon of mastocy-
tosis in neurofibroma lesions, but also highlights the possible 
close interaction between SCs and MCs in the neurofi-
broma progression via paracrine-mediated mechanisms.
However, although SCF is well known as a cytokine 
capable of enhancing development and multiple functions 
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Figure 2 CCL7 expression by SW10 Schwann cells (SC). (A) 
Relative expression level of CCR3 ligands (CCL3, CCL7, CCL8, and 
CCL13) was measured using quantitative polymerase chain reaction 
(qPCR). Relative expression level for each chemokine is shown atop 
the black bars. The expression signals for CCL3, CCL8 and CCL13 
could not reach threshold after 40 cycles of PCR reaction, thus their 
expression folds were all designated as 1. (B) CCL7 expression by 
SW10 SCs was further quantified by enzyme-linked immunosorbent 
assay using conditioned medium derived from SW10 culture. 
Absorbance level from SW10 culture conditioned medium was 
measured and the amount of CCL7 (43.91 ng/mL) was estimated 
against plotted standard curve. In comparison, the amount of CCL7 
in mast cell–conditioned medium was also tested (7.61ng/mL). (C) 
CCL7 expression by SCs detected by immunofluoresent staining. 
Representative frozen sections from neurofibroma lesions were 
stained with FITC-conjugated anti-CCL7 antibodies (left upper 
panel, green). Rhodamine-conjugated anti-SC GFAP antibodies 
were used to stain and specifically label SCs (right upper panel, red). 
Co-localization of CCL7, SCs and cell nuclei (DAPI stain, blue; left 
lower panel) were shown in right lower panel. Immunofluorescent 
staining was detected by confocal microscopy.
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of MCs including migration,30 given the marked cellular 
heterogeneity of neurofibroma and the complicated long-
travelled migration pathway of MCs, it is quite unlikely that 
SCF is the only factor to mediate MC migration and homing 
to neurofibroma. It should also be noted that SCF may also 
have inhibitory effect on chemotaxis of MCs according to a 
recent report.31 Other paracrine-mediated pathways, there-
fore, may well possibly also play important roles in the re-
cruitment and homing of MCs to the lesions of neurofibroma 
from peripheral blood. As chemokine and chemokine re-
ceptors have been well established to be essential for the 
migration of inflammatory or malignant cells to the lesions 
of many inflammatory or cancerous diseases,32 we there-
fore hypothesized that chemokine and chemokine recep-
tors may also play a role in the MC migration to the 
neurofibroma. Indeed, there have already been quite a few 
studies demonstrating that chemokine and chemokine re-
ceptors are important for MC trafficking to airways and in-
testine in either constitutive or pathological conditions.13,14 
However, to date, very few reports21 have specifically de-
scribed whether chemokine system may also play a role in 
the homing/migration pathway of MC to neurofibroma.
We next asked which chemokine receptor may be im-
portant for MC migration to neurofibroma. As CCR3 has 
been shown to be the only chemokine receptor maintained 
in CTMC after differentiation to mature cells20 and may 
play multiple pivotal roles in trafficking, effector function, 
and phenotype modification of MCs,15−20 we hence further 
hypothesize that SCs, being the progenitor cells for tumor for-
mation of neurofibroma, may attract MCs by CCR3-mediated 
mechanisms. Using mouse BM-CTMCs (a model of CTMC 
mimicking skin MCs)21 and SC line SW10, herein we have 
shown that CCR3-expressing BM-CTMCs are able to mi-
grate in response to SW10-derived conditioned medium in 
a CCL7-dependent fashion, thus supporting our postulation 
that CCR3 may also play a role in the migration and homing 
of MCs to the SC-initiated neurofibroma lesions.
We further found that survival of BM-CTMCs can be signifi-
cantly hampered by neutralization of CCL7 (data not shown), 
and hence postulated that autocrine-mediated, rather than 
paracrine-mediated reaction may govern the survival need 
for the MCs residing in the neurofibroma lesions, as evi-
denced by our finding that MC itself also express comparable 
amount (in comparison with SW10 SC) of CCL7, which is in 
A 6
5
4
M
ig
ra
tio
n 
in
de
x
3
2
1
0
0 10 100
CCL7 ng/mL
300 500
B 1.6
1.4
1.0
0.6
1.2
*
*
M
ig
ra
tio
n 
in
de
x
0.8
0.4
0.2
0.0
CCL7
200 ng/mL
CCL7
+ anti-CCL7
CCL7
+ isotype
CCL7
+ PTX
* *
C 8
7
6
5
4
M
ig
ra
tio
n 
in
de
x
3
2
1
0
Null SW10 CM SW10 CM
+ anti-CCL7
SW10 CM
+ isotype
SW10 CM
+ PTX
Figure 3 Chemotaxis assay for bone marrow–derived connective tissue–
type mast cells (BM-CTMC) in response to CCL7 and SW10 conditioned 
medium. (A) Migration of BM-CTMCs in response to CCL7 at different 
concentration; *p < 0.05 as compared with no CCL7 (0 ng/mL). (B) Migration 
of BM-CTMCs in response to CCL7 (at 200 ng/mL) with or without other 
agents (anti-CCL7, isotype IgG for anti-CCL7, or PTX); *p < 0.01 as com-
pared with CCL7 treatment alone (200 ng/mL). Note that the chemotaxis 
response to CCL7 could be blocked by anti-CCL7, but not by isotype 
IgG, indicating its specificity. (C) Migration of BM-CTMCs in response to 
either fresh medium or SW10 conditioned medium, with or without 
anti-CCL7 Ab, isotype IgG for anti-CCL7 Ab, or PTX; *p < 0.05 as compared 
with fresh medium control (null). PTX = pertussis toxin.
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Figure 4 Cell signaling assays for bone marrow–derived connective 
tissue–type mast cells (BM-CTMC). CCL7 treatment induces ERK and 
Akt phosphorylation in BM-CTMCs. In response to CCL7 treatment, 
the time-dependent accumulation of phosphorylated Erk 1/2 (pErk 1/2) 
was found in BM-CTMCs by immunoblotting (upper left panel). 
Moreover, the phosphorylation of another important signaling effector 
molecule, Akt, was also found increased (pAkt) above basal level with 
the presence of CCL7 (lower left panel). Neutralizing anti-CCL7 Abs 
were able to block both signaling event as shown in upper right panel 
(ERK) and lower right panel (Akt).
line with previous report that MCs may also express CCL7.33 
Certainly, it is quite possible that other paracrines or auto-
crines from MCs or other types of cells, in the complicated 
milieu of neurofibroma lesion, may also play a role in en-
hancing survival of MCs in the tumor.
Our finding that BM-CTMCs showed activation of ERK 
and Akt kinase pathway after CCL7 treatment is in accordance 
with previous reports.34,35 As Mocsai et al34 have demon-
strated that stimulation of GPCR may induce the phosphor-
ylation of ERK and Akt in BMMCs, Woo et al35 have shown 
that migration of leukemia MCs to another CCR3 ligand, 
CCL11 (also known as eotaxin), is dependent on ERK pathway. 
Our data of CCL7-induced signaling thus further support 
the role for CCR3 to mediate the migration of MCs to neu-
rofibroma lesions with expression of CCR3 ligands.
As NF-1 has been identified as the pathogenic gene for 
neurofibroma and has been shown to be important to medi-
ate MC migration (in deficient expression),1,2 we have also 
investigated the level of NF-1 expression by SW10 cells which 
serve as the model SC cells in our study. By qPCR, there is 
indeed less expression of NF-1 by SW10, in comparison 
with mouse fibroblast (NIH/3T3) and mouse endothelial (MS-
1) cells (data not shown). As previous reports have empha-
sized the indispensable role of NF1−/− SCs as the tumorigenic 
cells for neurofibroma, the fact that SW10 cells express less 
NF1 than other types of cells that are also present in the 
neurofibroma lesions (fibroblast and endothelial cells) is in 
accordance with current theory and hence support the use 
of SW10 cells as the representative SCs in this study. It will 
be interesting to see if further knockdown of NF1 gene will 
enhance tumorigenic natures of SW10.7
In present study, we have provided evidences that che-
mokine receptor CCR3 and its ligand CCL7 may play a role 
in the migration of MCs toward progenitor cells (SCs) for 
neurofibroma (paracrine-fashion) and may sustain MC’s sur-
vival in an autocrine way (Figure 5). Given that chemokine 
network has emerged as a promising therapeutic target for 
inflammatory disease, cancer, and viral infection, and there 
is still no effective therapy to date to contain the tumorigen-
esis of neurofibroma for NF1 patients, CCR3 or CCL7 may 
well serve as a potential target for the development of novel 
therapeutics for neurofibromatosis. Indeed, as Das et al36 
have demonstrated that small molecule antagonist against 
CCR3 may selectively inhibit eosinophil influx into the lung 
in mouse model of allergic inflammation, it will be important 
to investigate whether the migration of CCR3-expressing 
MCs and the subsequent tumor progression of neurofibroma 
may also be blocked by the similar approach.
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